ImmunityBio, Inc.
- Stock
- Ticker IBRX
- ISIN US45256X1037
- Nasdaq
Performance, volatility and drawdowns of ImmunityBio, Inc. since 11/2016, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.
Performance
$10,000 grew to $7,974. Global equities (VT): $29,042.
Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.
Declines from the peak
Lowest point −97.0% in 10/2023, measured from the peak in 02/2021. The old peak has not been reached again yet.
Financial statements
Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures
| Quarter end | 12/2024 | 03/2025 | 06/2025 | 09/2025 | 12/2025 | 03/2026 | 06/2026 | 09/2026 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | 7.6 | 17 | 26 | 32 | 38 | 44 | 51 | 49 |
| Gross profit | 7.6 | 16 | 26 | 32 | 38 | 44 | 51 | 48 |
| Operating income | -69 | -64 | -71 | -56 | -65 | -70 | -62 | -78 |
| EBITDA | -65 | -61 | -68 | -52 | -61 | -65 | -57 | -74 |
| Net income | -59 | -130 | -93 | -67 | -62 | -633 | -230 | -185 |
| Earnings per share | -0.09 | -0.15 | -0.10 | -0.07 | -0.06 | -0.62 | -0.22 | -0.18 |
| Balance sheet | ||||||||
| Total assets | 383 | 304 | 402 | 519 | 502 | 647 | 629 | 609 |
| Liabilities | 871 | 894 | 972 | 1,042 | 1,001 | 1,516 | 1,674 | 1,755 |
| Equity | -489 | -591 | -571 | -524 | -500 | -870 | -1,047 | -1,146 |
| Cash | 143 | 61 | 138 | 60 | 88 | 205 | 76 | 45 |
| Cash flow | ||||||||
| Operating cash flow | -85 | -86 | -80 | -69 | -70 | -75 | -66 | -75 |
| Capital expenditure | -2.1 | -1.1 | -1.1 | -0.7 | -0.9 | -1.8 | -3.5 | -2.9 |
| Free cash flow | -87 | -87 | -81 | -70 | -71 | -77 | -70 | -78 |
Value it:DCF calculatorMultiples calculator
Annual returns
Best year 2020 at +251.7%, weakest 2018 at −74.2%. 2 of 9 full years were positive. * partial year.
Quarterly reports
Filing date with the SEC and earnings per share of the quarter
| Day | Earnings per share |
|---|---|
| 9 Nov 2026 | −$0.18 |
| 4 Aug 2026 | −$0.22 |
| 7 May 2026 | −$0.62 |
| 23 Feb 2026 | −$0.06 |
| 5 Nov 2025 | −$0.07 |
| 5 Aug 2025 | −$0.10 |
| 12 May 2025 | −$0.15 |
| 3 Mar 2025 | −$0.09 |
| 12 Nov 2024 | −$0.14 |
| 12 Aug 2024 | −$0.20 |
| 9 May 2024 | −$0.20 |
| 19 Mar 2024 | −$0.38 |
Key metrics
Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.
Valuation
- Market cap
- €5.8bn
- Market cap in trading currency
- $6.40bn
- Enterprise value
- $6.07bn
- P/E
- –
- P/S
- 35.08
- P/B
- –
- EV/Sales
- 33.25
- EV/EBITDA
- –
- Earnings yield
- –
- FCF yield
- -4.6%
Results (last four quarters)
- Revenue
- $183m
- Gross profit
- $180m
- EBITDA
- −$258m
- Net income
- −$1.11bn
- Earnings per share
- −$1.08
- Revenue per share
- $0.17
- Revenue growth
- +52.3%
- Earnings growth
- –
Profitability
- Gross margin
- 98.8%
- Operating margin
- -150.2%
- Net margin
- -607.8%
- Return on equity
- –
- Return on assets
- -182.1%
Balance sheet and cash flow
- Cash
- $334m
- Cash per share
- $0.31
- Financial debt
- –
- Debt/equity %
- –
- Current ratio
- 4.27
- Book value per share
- −$1.08
- Operating cash flow
- −$288m
- Free cash flow
- −$297m
Dividend
- Dividend yield
- 0.00%
- Dividend (12 months)
- $0.00
- Yield (12 months)
- 0.00%
- Payout ratio
- –
- Ex-dividend date
- –
Shares and trading
- Shares outstanding
- 1.06bn
- Volume
- 10.5m
- Avg. volume 3 months
- 12.7m
- Relative volume
- 0.8
Price and technicals
- Price
- $6.02
- 1 day
- −8.4%
- 52-week high
- $11.55
- 52-week low
- $1.98
- Distance to 52-week high
- −47.9%
- Distance to 52-week low
- +204.0%
- Distance to 50-day line
- −28.5%
- Distance to 200-day line
- −24.5%
- RSI (14)
- 36
- Volatility 1M
- 113.3%
Performance
- 1 week
- 0.0%
- 1 month
- −27.6%
- 3 months
- −20.6%
- 6 months
- −16.6%
- YTD
- +204.0%
- 1 year
- +181.3%
Dates
- Fiscal year end
- 31 Dec 2025
- Most recent quarter
- 30 Sep 2026
Frequently asked questions
How has IBRX performed since 11/2016?
$10,000 grew to $7,974 by 20 Nov 2026, which is −2.2% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.
How volatile is IBRX?
Volatility was 124.9% per year, measured on monthly returns. The largest decline from a peak was −97.0%, with the low in 10/2023.
How does IBRX compare with a broad equity ETF?
Over the same period Global equities (VT) returned +11.3% per year at 15.1% volatility, IBRX returned −2.2% at 124.9%. The correlation of monthly returns was 0.18; 1 would mean they moved in lockstep.
Which currency are the figures in?
In US dollars, the currency of the US listing.